Two major catalysts will drive long-term growth for cannabis. One, major retailers are just beginning to embrace CBD thanks to sizable consumer demand. To date, Neiman Marcus, Sephora, Vitamin Shoppe, Kroger, Barney's DSW, CVS, American Eagle, and Walgreen's have all jumped at the opportunity. Now, (full story)
VSI: 6.50 (unch), CBDN.CN: 0.440 (+0.045), GTII.CN: 10.900 (-0.080), GTBIF: 8.2700 (-0.0523), CWBHF: 8.6772 (-0.0328), CWEB.CN: 19.300 (+0.350)
Following the recent legalization of cannabis in Canada and the continued efforts in the U.S., a plethora of recreational dispensaries began to emerge. Recreational dispensaries sell cannabis-based products such as flowers, oils, tinctures, topicals, and many others, which anyone can purchase as lon (full story)
CRFTF: 0.0645 (-0.0044), CRFT.CN: 0.085 (-0.010), CRON: 6.82 (-0.01), CRON.TO: 8.98 (-0.09), APHA: 4.89 (-0.06), APHA.TO: 6.45 (-0.10)
Another drug may soon follow it the footsteps of cannabis -- psilocybin mushrooms. In fact, analysts argue mushrooms may hold untapped medical properties that could be used to help treat depression and addiction. Better, the U.S. FDA already granted "breakthrough status" to COMPASS Pathways' psiloc (full story)
BOSS.CN: 0.235 (-0.005), BOSQF: 0.1798 (-0.0002), GWPH: 102.88 (+0.42), TLRY: 18.20 (-0.35), APHA: 4.89 (-0.06), APHA.TO: 6.45 (-0.10), CWEB.CN: 19.300 (+0.350)
Cannabis has been one of the hottest investment stories of the year thanks to the U.S. Farm Bill, growing acceptance among Americans, news of legalization throughout the U.S., and a sizable push by retailers to stock shelves for demanding consumers. All as millions of people living all over the wor (full story)
CWEB.CN: 19.300 (+0.350), VFRM: 1.1100 (-0.1600), CWBHF: 8.6772 (-0.0328), GGB.CN: 0.900 (-0.170), GGBXF: 0.6881 (-0.1174), GTII.CN: 10.900 (-0.080)
CBD retail sales just in the U.S. are expected to pass $1 billion - a 133% jump year over year, as noted by the 2019 Hemp & CBD Industry Factbook. By 2024, sales could balloon to $10 billion. "The recent surge of consumer demand for CBD, coupled with increasingly easy access to CBD products, is ex (full story)
Performance Comparison
Key Statistics
Annual EPS | 0.120 |
---|---|
Dividend & Yield | -- (--) |
P/E Ratio | 119.202 |
Market Capitalization, $K | 489,743 |
Weighted Alpha | +59.75 |
Standard Deviation | +0.43 |
Profit Margin | 0.17% |
Beta | N/A |
Growth Rates
YTD | +27.22% | |||
1-Year | +83.81% |